Sarah E. (Janes) Land DO

Psychiatry•Tulsa, OK

Physician

Join to View Full Profile

3314 E 46th StSte 200Tulsa, OK 74135
Phone+1 918-591-2510
Fax+1 918-591-2511

Education & Training

University of Oklahoma School of Community Medicine (Tulsa)Residency, Psychiatry, 2003 - 2007
Oklahoma State University Center for Health SciencesClass of 2003

Certifications & Licensure

OK State License 2004 - 2025
American Board of Psychiatry and Neurology Psychiatry
AOA Board of Neurology and Psychiatry Psychiatry
American Board of Obesity Medicine Obesity Medicine
National Board of Physicians and Surgeons Psychiatry

Clinical Trials

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3) Start of enrollment: 2021 Aug 27
Recruiting
Phase 3
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease Start of enrollment: 2022 Jun 02
TERMINATED
PHASE3
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults with Fragile X Syndrome Start of enrollment: 2021 Sep 13
RECRUITING
PHASE3
Memory Improvement Through Nicotine Dosing (MIND) Study Start of enrollment: 2017 Jan 13
ACTIVE_NOT_RECRUITING
PHASE2
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS Start of enrollment: 2018 Nov 09
ENROLLING_BY_INVITATION
PHASE2, PHASE3
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid Start of enrollment: 2020 Jul 14
ACTIVE_NOT_RECRUITING
PHASE3
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Start of enrollment: 2021 May 18
ACTIVE_NOT_RECRUITING
PHASE3
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Start of enrollment: 2021 May 18
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) Start of enrollment: 2020 Jun 19
ACTIVE_NOT_RECRUITING
PHASE3
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Start of enrollment: 2014 Feb 28
Completed
Phase 3
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder Start of enrollment: 2020 Dec 22
RECRUITING
PHASE3
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder Start of enrollment: 2021 Mar 30
ENROLLING_BY_INVITATION
PHASE3
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study Start of enrollment: 2015 Sep 08
Completed
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease Start of enrollment: 2022 Aug 15
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD) Start of enrollment: 2020 May 22
Terminated
Phase 3
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects Start of enrollment: 2021 Mar 01
COMPLETED
PHASE2
Join now to see all

Professional Memberships

American Osteopathic Association - AOA
Member
Obesity Medicine Association
Member
American Board of Obesity Medicine
Member

External Links

Central States Research https://centralstatesresearch.com/
Mind Spa https://www.mindspaoklahoma.com/